Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Clinical Outcomes of Graves’ Ophthalmopathy Treated with Intensity Modulated Radiation Therapy
source: Radiation Oncology
authors: Li YJ, Luo Y, He WM, Li P, Wang Fsummary/abstract:
Radiation for Graves’ ophthalmopathy (GO) has traditionally utilized lateral opposing fields (LOF) or three-dimensional conformal radiotherapy (3DCRT) technique. The current study was conducted to report clinical outcomes and therapeutic effects of intensity modulated radiation therapy (IMRT) in treating GO patients.
One hundred sixteen patients with GO were treated with IMRT as initial local therapy between July 2010 and August 2013, with a median follow-up of 62 months (range 45–81 months). Radiotherapy dose was 20 Gy in 10 fractions within two to three weeks. The immediate and long-term response to IMRT was evaluated in GO severity score and in each category of symptoms. Acute and long-term complications were recorded to assess its safety.
Symptom severity score significantly fell from the start of treatment to 4- or 6- month post-IMRT (P < 0.01). In total, 85 patients (73.3%) experienced improvement of GO symptoms in the first half-year, and only 4 of them (4.7%) suffered recurrence of the GO symptoms during the subsequent follow-ups. Orbital pain, tearing and extraocular muscle dysfunction had the best treatment reaction to IMRT, while proptosis and blurred vision were the most refractory symptoms. Acute complications were slight and self-limited, mainly including intermittent eye redness in 9 patients (7.8%), sideburns hair loss in 19 patients (16.4%), increased milphosis or madarosis in 23 patients (19.8%) and pseudo-progression of GO symptoms in 15 patients (12.9%). For long-term complications, chronic xerophthalmias occurred in 7 patients (6.03%), cataract developed in 2 patients (1.72%), and all were well-managed by medical interventions. Radiation retinopathy and secondary malignancy was not presented in the cohort.
The study demonstrated that IMRT could serve as a viable option in treating GO patients, with a satisfactory symptom control ability, and relatively slight and acceptable post-radiotherapeutic complications.
read more full text
Graves’ Disease Symposium Questions and Answers (Pediatric)https://www.youtube.com/watch?v=EtKbS0zE...
Brian Chuck Tse, MDBrian Chuck Tse is an Assistant Professo...
Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves’ OrbitopathyImportance: Graves orbitopathy (GO) res...
Prem Subramanian, MD, PhDPrem S. Subramanian is the Professor of ...
Black & Rare: Thyroid Eye Disease Webinarhttps://www.youtube.com/watch?v=lzkSVY4E...
Thyroid Eye DisordersWhat is the Thyroid? The thyroid is a b...
Disease Presentation and Remission Rate in Graves’ Disease Treated With Antithyroid Drugs: Is Gender Really a ...Objective: Male gender is considered an...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.